Skip to main content
Beijing Luzhu Biotechnology Co., Ltd. logo

Beijing Luzhu Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 2480 ISIN · CNE100005YD8 HKEX Manufacturing
Open in API
Filings indexed 131 across all filing types
Latest filing 2026-05-18 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 2480

About Beijing Luzhu Biotechnology Co., Ltd.

http://www.luzhubiotech.com

Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company specializing in the research, development, production, and commercialization of innovative human vaccines and therapeutic biologics, including bispecific antibody drugs. The company's pipeline targets disease prevention and treatment, addressing significant clinical needs. Its core product is the recombinant Herpes Zoster Vaccine (LZ901). LZ901 has achieved positive immunogenicity and safety data in head-to-head clinical trials against a leading market competitor, with findings published in Nature Communications. The Biologics License Application (BLA) for LZ901 has been accepted by the National Medical Products Administration (NMPA). Luzhu Biotechnology employs a strategy combining proprietary R&D with the integration of advanced international technologies.

Recent filings

Filing Released Lang Actions
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 12, 2026
Proxy Solicitation & Information Statement Classification · 88% confidence The document is a form of proxy relating to the Annual General Meeting scheduled for June 12, 2026. It is part of the materials sent to shareholders to solicit voting instructions (i.e., proxy solicitation) rather than a substantive report, earnings release, or voting results. This fits the Proxy Solicitation & Information Statement category.
2026-05-18 English
NOTICE OF 2026 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 87% confidence The document is the formal notice of the company’s 2026 Annual General Meeting, with detailed resolutions to be voted on and proxy instructions. It is a solicitation of votes and provision of meeting information, not the actual annual report, financial statements, or call transcript. Therefore it falls under “Proxy Solicitation & Information Statement.”
2026-05-18 English
CIRCULAR OF THE 2026 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a shareholder circular containing the formal notice of the 2026 Annual General Meeting, detailed resolutions to be voted on (including adoption of the 2025 annual report, re-appointment of auditors, share issuance and repurchase mandates, profit distribution plan, etc.), and proxy instructions. It is not the annual report itself but a solicitation of votes and information statement ahead of the AGM, which matches the Proxy Solicitation & Information Statement category.
2026-05-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report for movements in securities, specifically for the month ended 30 April 2026, submitted to the Hong Kong Exchanges and Clearing Limited. It includes detailed information on movements in authorized/registered share capital, issued shares, treasury shares, public float sufficiency confirmation, and confirmations related to compliance with listing rules. The document is structured as a regulatory submission with no financial statements or earnings data, nor is it an announcement of a report publication. It is not a full annual or interim report, nor a call transcript or management report. The content aligns with regulatory filings related to share capital and securities movements under exchange listing rules. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-05-05 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report' for the year 2025, issued by Beijing Luzhu Biotechnology Co., Ltd. It contains comprehensive sections including corporate information, financial highlights, management discussion and analysis, auditor's report, and consolidated financial statements. It meets all criteria for a full annual report. FY 2025
2026-04-23 English
CHANGE IN USE OF PROCEEDS
Capital/Financing Update Classification · 89% confidence The document is a formal stock exchange announcement by Beijing Luzhu Biotechnology Co., Ltd. regarding a board resolution to change the use of unutilized net proceeds from its previous global offering. It is not an AGM presentation, annual or interim report, earnings release, or audit report; instead it provides an update on capital raised (the Global Offering) and how those funds will be reallocated. This fits the “Capital/Financing Update” category (CAP).
2026-04-23 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.